Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
SNTA > SEC Filings for SNTA > Form 8-K on 16-Sep-2013All Recent SEC Filings

Show all filings for SYNTA PHARMACEUTICALS CORP

Form 8-K for SYNTA PHARMACEUTICALS CORP


16-Sep-2013

Other Events, Financial Statements and Exhibits


ITEM 8.01 Other Events.

On September 12, 2013, Synta Pharmaceuticals Corp. issued a press release announcing that the U.S. Food and Drug Administration granted Fast Track designation to the investigation of ganetespib, Synta's lead Hsp90 inhibitor drug candidate, to improve overall survival when administered in combination with docetaxel for the treatment of patients with metastatic non-small cell lung adenocarcinoma who have progressed following one prior chemotherapy regimen. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.



ITEM 9.01 Financial Statements and Exhibits.

(d)                 Exhibits.



Exhibit
Number                  Description

99.1      Press Release, dated September 12, 2013


  Add SNTA to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for SNTA - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.